← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections
narlaprevir
J05AP14
Forms & Strengths
- 100mg and 200mg tablets
- co-administered with ritonavir
Adult Dosing
- 800-1000mg per day in combination with ritonavir
- divided into 2 doses per day
Pediatric Dosing
- safety and efficacy not established in pediatric patients
- use not recommended in pediatric patients
Indications
- treatment of genotype 1 chronic hepatitis C virus infection
- combination with ribavirin and peginterferon alfa
Mechanism of Action
- inhibits the NS3/4A protease of hepatitis C virus
- prevents viral replication by blocking polyprotein processing
Contraindications
- combination with ritonavir in patients with severe hepatic impairment
- combination with certain medications, e.g. alfuzosin, ergot derivatives
Adverse Reactions
- anemia
- neutropenia
- skin rash
- gastrointestinal upset
Drug Interactions
- increased levels of statins, e.g. atorvastatin, rosuvastatin
- decreased levels of narlaprevir with certain anticonvulsants, e.g. carbamazepine
Curated Content: Needs Vetting Before Put to Clinical Use